Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No prob there's more active discussion on SH and ceo.
Absolute real deal here. The market will catch on in due time. Meantime, load the boat.
Guess who wrote the article.
Arthur Herman
I am a Senior Fellow at the Hudson Institute and Director of the Quantum Alliance Initiative, and co-author of “Quantum Computing: How To Address the National Security Risk” (Hudson Institute, August 2018). I’m also the Pulitzer Prize Finalist author of nine books, including Freedom’s Forge: How American Business Produced Victory in World War II (2012); 1917: Lenin, Wilson, and the Birth of the New World Disorder (2017); and the New York Times best-seller How The Scots Invented the Modern World (2001).
https://www.forbes.com/sites/arthurherman/2021/08/20/blazing-new-paths-in-quantum-security/?sh=534f4f6e613a
"Two new companies, however, have taken these two approaches in new directions. Their hybrid approach to quantum security is both intriguing and perhaps a harbinger of where quantum security is headed in the future.
Quantum eMotion, for example, a Canada-based company, has taken the QRNG route without relying on QKD for deployment. Instead, their random number generator is embedded in a portable USB-type key or microprocessor chip, so that it can be literally a plug-and-play solution for protection against cyber hackers. Based in Montreal and relying on decades of research at Sherbrooke University by physics professor Bertrand Roulet, Quantum eMotion’s goal is to expand the advantages of quantum randomness to mobile phones, computers, the Internet of Things (IoT), blockchain, and the cloud, without having to rely on the often-expensive infrastructure and design architecture QKD requires.
Quantum eMotion also has the added feature of being the only QRNG company in the world that is publicly traded, on the Toronto Stock Exchange. This marks the beginning of a trend as quantum start-ups look beyond the venture capital route for raising money—a sign that the quantum communication technology sector is gaining maturity."
Massive news today. If the Robinhood traders catch wind look out above. Massive US California expansion set for Q2 21 hang onto your shares this could hit double digits next year at this rate of expansion and US market acceptance.
@newsfile The Very Good Food Company Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail @newsfile/the-very-good-food-company-announces-distribution-partnership $VRYYF $VERY $0SI $CA88340B1094
NEWS OUT September Trials
https://ceo.ca/@nasdaq/revive-therapeutics-update-following-us-fda-approval
Is Boulware part of Revive?
Recovering nicely. Had a bit of Sykes OTC drama to deal with but getting back on track. Sheesh lol.
Now that the OTC rape is done and cooler heads prevail, read the news again:
31 Jul 2020, 08:39
Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
“The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,” said Michael Frank, Revive’s Chief Executive Officer. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.”
About the Phase 3 Confirmatory Clinical Study
The Phase 3 confirmatory clinical study titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo.
The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of first dose through Day 28 following randomization. Efficacy will be assessed by comparison of clinical outcome (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID-19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo.
Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation.
An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for a total of 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports.
RVV level 2 on the Canadian side looking good. 34 and 35 offering small resistance. Oversold thanks to the crazy kids in the OTC lol.
CBC going to cover RVV?
No public company that I'm aware of in Canada in phase 3 other than RVV.
"Some of the top companies to watch as they race to treat the virus include Revive Therapeutics (CSE:RVV)(OTC:RVVTF), Gilead Sciences Inc. (NASDAQ:GILD), Novavax Inc. (NASDAQ:NVAX), Moderna Inc. (NASDAQ:MRNA), and GlaxoSmithKline PLC (NYSE:GSK)."
Revive mentioned with the giants. Wow nice.
25 c Euro is pointing to a flat open so far but all markets follow the Canadian trade so Canada will dictate the day today. Undervalued no matter how we slice it.
29 c Euro is 34 c USD or 45 c Canadian so technically the Canadian and US trade should open green.
Canadian stock so Canada leads the trade. So today's trade was essentially and literally a wash flat close.
I'm surprised RVVTF still traded today with the Canadian parent ticker on holiday. Very easy to manipulate in a scenario like this.
Stay focused on the fact that Revive has been awarded FDA fast track phase 3 approval and as cooler heads prevail the market valuation has a lot of runway upwards.
So the last minute pull back was because a group wanted to play RLFTF? No worries, Canada is back online tomorrow and RVV is a Canadian stock with a US FDA PHASE 3 FAST TRACK APPROVAL. Remains very undervalued I expect a green day tomorrow. :)
Canada will lead the way tomorrow. No worries.
They received an extension for a few months so they have time to get the stock over $1.00
$0.43 after hours. :)
Hello everyone, I am building a sizeable position here quietly. This stock can surprise many to the upside imo. Glta.
This will break out nicely now by the looks of it.
This will break out nicely now by the looks of it.
Well the one silver lining we got is that we're already beaten to a pulp so it is anyone's guess where we trend tomorrow. But my gut says up as the day rollls along.
Possible yes but depends on what kind of support we have. We are about to find out.
I know that the PIF took 8% of the company. Not sure what you mean. I think CCL is already at rock bottom pricing.
Because a May 15 ban would have seen a much higher share price. The market likely suspected it would be into the early summer for resumption - hence the 75 to 80 percent drop in the sector. That's my thought. We'll see.
Hence the 75 to 80 percent drop in the sector. Baked in.
Wanna bet?
Lol. "Up to 100 days or less" is July or sooner. Carnival is taking online orders for July if you check their site.
Cruise liners are already down 75 to 80 percent. Bad news is priced in imo.
I completely understand your perspective. No offence taken at all. Following the distancing protocols are very important. Hopefully there's a strategic and responsible happy medium to get the country functioning again once cases peak out and level off. The country simply cannot afford to be shut down for much longer.
People need to get back to work hopefully soon or we will have more problems than the virus itself. That's my concern. Wear PPE in the workplace and keep the distancing intact until we get the all clear as another strategy.
Isolate the elderly and anyone with high risk underlying conditions. Simple. No need to keep the country shut down for much longer.
Guys, they did not shut the country down when Swine Flu happened. The media is spreading fear big time. Swine Flu was pretty bad as well. Turn the TV off. Every city wants to milk the stimulus. There is a large political smoke screen behind this.
"In 2009, CDC estimated there were 60.8 million cases (range: 43.3-89.3 million), 274,304 hospitalizations (range: 195,086-402,719), and 12,469 deaths (range: 8868-18,306) in the United States due to the (H1N1) Swine Flu virus."
That's very good. At the end of the day CCL stock is more than 4 times lower than the peak so there is a lot of value here as things slowly but surely get back to some kind of normalcy.
That's correct. It will be a gradual rise to normalcy. Which means markets slowly but steadily rise. New bull market.
They will likely strategically open in May with some easing restrictions.
(excluding potentially existing hot spots - they'll keep focus on those areas that need it) Imo. Quebec in Canada is considering full reopen based on positive case/death data.
Book your cruise. :)